Publication

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase Ill KEYNOTE-426 study

Powles, T
; 
Plimack, ER
; 
Stus, V
; 
Gafanov, RA
; 
Hawkins, Robert E
; 
Nosov, D
; 
Pouliot, F
; 
Alekseev, BY
; 
Soulieres, D
; 
Melichar, B
... show 10 more
Citations
Altmetric:
Abstract
Authors
Powles, T
Plimack, ER
Stus, V
Gafanov, RA
Hawkins, Robert E
Nosov, D
Pouliot, F
Alekseev, BY
Soulieres, D
Melichar, B
Vynnychenko, I
Kryzhanivska, A
Bondarenko, I
Azevedo, SJ
Borchiellini, D
Shou, Q
Perini, RF
Chen, M
Atkins, MB
Rini, BI
Affiliation
Barts Health and the Royal Free NHS Trusts, Barts Cancer Institute, Queen Mary University of London, London,
Description
Date
2019
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Powles T, Plimack ER, Stus V, Gafanov RA, Hawkins RE, Nosov D, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study. J Clin Oncol. 2019;37(7_suppl):543-.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/622475
Embedded videos